N
Google TrendARSENAL (5000+) — Arsenal v Lille: Champions League – live
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:arsenal5000+anthony gordon500+montez sweat2000+rob lowe1000+tanner hudson500+frozen frenzy200+huevo1000+payton pritchard1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Phase 3 Trial for Myotoni" (30 stories)

Top Headline Story

Evaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trial
Lead StoryNeurologyLivegeneral
Sep 29

Evaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trial

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPdnI3bUZla0Jwb1REYWZfeWMtdVFHQk8zMWFZMEJnRGNDMU54OGVuUmk1cThUcktfSlJZdmxMUmpkeG9SUGF4a3p6ZFpCUDBGNkphLXJwU3JOaG5kRU9xWG5TajItT1RHMWc2aUxmZkNKVkNqaTNWcnVyVi04RXUySEtCZnpDZHhjeUtGbU5IT0ZKenVWbVFhTXlKS3NGRTF6MS0zQnJ5YnNSX2VTZnlWLXRrdHFfQWs?oc=5" target="_blank">Evaluating Zeleciment Basivarsen in Myotonic Dystrophy Type 1: The Phase 3 HARMONIA Trial</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+22m ago

arsenal

Arsenal v Lille: Champions League – live

Filter stories
500+22m ago

anthony gordon

Anthony Gordon's first Barcelona goal, Manuel Neuer's mistake and Djed Spence's Inter debut in the Euro Debrief

Filter stories
2000+32m ago

montez sweat

Bears DE Montez Sweat suspended two games for violating NFL's PED policy

Filter stories
1000+42m ago

rob lowe

Ben Shapiro’s Star-Studded ‘Confession’ Film Includes James Franco, Rob Lowe And More

Filter stories

Search Results for "Phase 3 Trial for Myotoni"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Neuromuscular drug from Novartis fails in key study, adding to pressure on company
STATtech

Neuromuscular drug from Novartis fails in key study, adding to pressure on company

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOZnA0UjRRNFZudTRlb1lFeUtna1lmUXJqRl9uZG10bm1JMlU5am4wc2EyXzhZd2hldWlDcnI4emdweW9PU0dtQVVGTnVjOVJxcVhxTXJ1OWtOUlNra19KZVNocmhxM0ZTaFdIZ0tQZVFBQmdUT0JiMW03ZzlHXzRyNDhidURLVDNnVzU3cU5ydTdQT3I0M1ZSaW5VbHBDZk9MNXlMcG1JLUQwZWFYMG5jdQ?oc=5" target="_blank">Neuromuscular drug from Novartis fails in key study, adding to pressure on company</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Dyne Announces Promising Phase 3 HARMONIA Trial for DM1
The Clinical Trial Vanguardworld

Dyne Announces Promising Phase 3 HARMONIA Trial for DM1

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOV2poNlVOSFI1RmxENG5CTlkzZkw4UV9mT1ZoSGh0MGxWUTdQQVMxVnFfTl9kSUpEQjFHSEVwejQ2UFltX19wZmgtX0NKeGQ4aEJSQ3hEZE0yaHFqcHpMZnNsT2MxVjBDWkRleTJwd2laeEV1ODdZVnlZUU1Fb3hyV0NtZGVlZ3ZaNmRFZFJ6SGdEaXRtaUg3dzZtSFJfRXJZ?oc=5" target="_blank">Dyne Announces Promising Phase 3 HARMONIA Trial for DM1</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
MDA 2026: Dyne therapy boosts strength, cognition in DM1
Muscular Dystrophy Newsgeneral

MDA 2026: Dyne therapy boosts strength, cognition in DM1

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPRkdqQk1RQVU5ZWE3UDNwUHFlZ0RtbzFjdGFITEh1WFVKbDF3bVVzTmhpLUNxa1AtenUtUndwQjZyUnFTSnBFV0FxMF9NYVlRekNROWplSVpWZ2hlekFzekl0WUdIVkgzOGZRWi1SM2ZsZks1N1ItRTc0MXd4eFdubnBVTTNmbGdNR2tzSWVvbzVVckpETFE?oc=5" target="_blank">MDA 2026: Dyne therapy boosts strength, cognition in DM1</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
PR Newswiregeneral

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

<a href="https://news.google.com/rss/articles/CBMivgJBVV95cUxQZHJFcWVuYzNDZmR6MDVPbnhtTE5SeTI1aDhUZW9iYTBlS2RBTzFoRW00Y1NjdDk5a0g5TFFQdUlJbW1Zb2JocWV4T1lpd0I4ZjdlUmE3Vk5keGZnV3ktZVJiVG8xYjltV3hZZ2FIekxCb0hKaFpXVk1mZTNDdUpMZ3ZscVRwM1l1ek1nY3RncWF6Zno0a0h4TFdxR0k1WGhCN0Y0akYtSTh6Tlprd2tOMVYxNS1OM2ZTOVNTazNsSmVlN2ZFbXYxbjE0RXdRb1ZhaEk3SlZabVJjVkppSHloMWhKZHhXS3RsNjVMYjFMd2lzcnREUEpaNTZySHQyU3o4RFF1dHBkRXI1UWY5QS1ZOWNiS0JDVHNHRERoTGpteEIycVltQzF4TUxVREFOb21QSG5lWUFZOVV0ZG03X1E?oc=5" target="_blank">The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial
Genetic Engineering and Biotechnology Newstech

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNcm5RWG1adGtpOE9iVUJoOEhFMGI0aER1enJ6Qkl5N3ZaVHZsRWw1SnRMZzNKM29JRDdjUWl4Nm85MTJGTzhGelltZUdRbVQwTDlHZzFLUUdkRU9SQzlvUEVtYkVvRFB4NklROHByMTI1UW9zWTZmeHlHT1pZTFZ2ZU5HSDY1NGVqN2N0T0h3cUNLRS1qazI1SU5tbnkxcEJRTW5SMUlvUmRMTnhDcHJ0RzN4aUJSZ3NTX2VxaDlJeVVhQ1FIWGQ2MGxzRXRfZ29SQXhOUDJCVjhfNEVkRVpfYlFxdDJGbVVo?oc=5" target="_blank">Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryMore like this
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
GlobeNewswiregeneral

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxNUHkxczMwWDl1WndTOFhOTG5RcVVpbmtrbmNVQ0toVGNtYUFIc3pPdjVfOHRlTnE1QTJQcVFFSERIR1RIZDlnRGg1MFptMXAwakZDZWhWYk91aVprdVJqa0J5LU1LNkpIR3BnNGlqOGpWakJfQnFKWUFod0JBOWhWUktDMTZPNEVyVUJsQWpZOWhmMkpldjJpOF9TZ1ZzeDNkdzVnSkpwSGEtUmk3N3VqdUhXcXdoa1NNTkV6bkF0a3pqZWdpc1lDMlJpMnVIOXZKVk9JNWY1eDVOMTlkR0gwNWhvQ3JRd0Rqc3U2b05kS3FScmJBYmMxUTBYRjhqS1VsVTRZdXVjT2R0YlFLNWZUbVNTZENTWnZzNW5EcFJpMzBrUlV6M1NWclM0SDcxWmx5Nnc?oc=5" target="_blank">Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
BioSpacegeneral

Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQQm9HM0d2VEZMdmMxaE9feWVxNmEzazdxNERWNnJTTUhLYlc1T0h1ZVg0WVpPS3MyMEt3MS0xbEI4SVZLVEhjVDdldXFZaGQ0YjRldXVxb05FUEhaTDU3clQ2Yk5kaUhhYVFHZ253NkljSzNGcXFjVldLaThmd2dVcEJtLTlQbDVfeXk5LV9lTS1qOEx5VUcwYnVBZm5IRjIwQ2stSTNYbjNDTm53ekJJVmxQeGpvQVVsRlV2QWNNSHlWVzJSa0E?oc=5" target="_blank">Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Proactive financial newsworld

Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPMmNMaGs2Wl9XdEhROU13a2R5T0tRdG1hR1VtU1czV1lUUTk5RmNRZG5wU294cWM0WnNTY0FSaTBDeUw5T2VzVDJOQU1NdGhMVUkxcTEySGc5MFZ0WDI0THF0dnIxc29zR0p4WmR1Qi1aOVc1bXdQSVMwXzFVcndOQWJhLW4ybFlBWDc2clRFM0ZPc3ltczIzaEVTalZuMlR4dG1VcE1SQzg4NkR5aEpfcU9uOUZCU1JhUTV1MTZhNW9yN0hCSlYwYXhyMThvVmE4emJpUTdUQ2dxWE85aDRr?oc=5" target="_blank">Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial</a>  <font color="#6f6f6f">Proactive financial news</font>

Read Full StoryMore like this
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Benzingageneral

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQWUU4dFJLSm5VazcyZmVVV3ctOTFrNjIySVlIeFpHXzFfM3hFS1hER1QwR1Nyel93N1R2Ync4YlpZd1pRWWlhU2lNN3JxUjhnRUxVbWV3bGZ6MWZBVkp6bVZnTXVVSHRRME1nVmZpMFFiYWsyZk5GQ1JfaC1yR21Yc1lSQm9MUDcxZC1QckY4dW1aX19hWkgwZ0lnWTJxa3FEQkp6Tmg5RFY0aTYzVFNwU2I4RHZxaGoxZUFUcWdXWDNBU0lUOVZ3OFFPeTVoVWs?oc=5" target="_blank">Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling</a>  <font color="#6f6f6f">Benzinga</font>

Read Full StoryMore like this
Dyne commences Phase III HARMONIA trial for DM1 therapy
Clinical Trials Arenageneral

Dyne commences Phase III HARMONIA trial for DM1 therapy

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNUWZRb2M5VkNsbzNGcGc2RmdjQ2FNVzlVbDE1ZUNicTNSSFZqYjhNQ29FNzM0Y3JEVHQ0TF9veThjbW9FZWRUYnZoWUU2TFd4aVllUS0xekdibkdUWnVGRENFM1RZd2E2Nkx6UW9VMEd1c21USHpRVmMyaFZMZm42SjdoYkV0LWs?oc=5" target="_blank">Dyne commences Phase III HARMONIA trial for DM1 therapy</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
proactiveinvestors.com.auworld

Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxOYkdTVXhJRzdXNmFKZHpHeUFiNVl3d0dZcnBxMG1JX0JldzFCaWl5MjFwci1iNDRyeW5UQkRvMkVVVm1kXzI4c2IweVNXenV1THZ5M25sbHBvb1JxSXlyeWpqblE1cjVpbGxpeVd0R2Q3b284NllrcUlCUkl3RVhFYldmaVZmNHdianJuSFlKODNSUVB5RDJRcGZSUUMwTzhGQWxXWnc2M3hyLUQ1aG9CeVlrckdoR21qbEtoNUdCRlF0WC03Z3BfYUxHMlNkVEZCUEJDSmVqeGFocFFGMFJGRkhGQQ?oc=5" target="_blank">Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial</a>  <font color="#6f6f6f">proactiveinvestors.com.au</font>

Read Full StoryMore like this
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA
GlobeNewswireworld

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA

<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxOcGNMcjNheklKZ3Y5b0syRHhjcEdmeGg5R1FSRDJuMTBQdXB3bVc4SGFVc2pNeVE5dmhyWUo5M3ZnXzQzT05tR29tc3BidGs5dFdFYnZEbEdNdjQzcm14VHVxSFVpNEFQUVBub3BOOERES2dmdHV4alZjWEp2dE9uaWxaYjVoNWplSUZ3YU1wUkhRSkFzcjVUQS1tbklIXy1ESTZaVmZaLVlvZlVwOVd0ZUdXV0Q0N0ZPTnNuMzFpLThjVUNpWVpEOXBVMEJUMW1BTkY3LVdxODVIYVAtM0JoeUhIQ2k2SEpUb1JzZ3BnNktudUZQYVJMc19oN3hwTTF0WWtHSmNpLWR4aTJiOGtZbTBDNA?oc=5" target="_blank">Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Dyne Therapeutics Announces Completion of Enrollment in
GlobeNewswireworld

Dyne Therapeutics Announces Completion of Enrollment in

<a href="https://news.google.com/rss/articles/CBMiygJBVV95cUxONHFSRUZzdi0yUmlEaE54NzlFYmVmSGlzLW5qNFp5NFlRSFhVYjI4U0prb2JJd013ODhhaTE3aUNpRFBmZkFVaklnM0QydVp0ek9KTFByaWZBREFNV1ZFTVpRSjJRQV8zVnlCYWV5X05TeE1DazdHbzluUlVwaThYcEMzek1OUG9uSm9OOGZCNU4zM1VYbWVPd2VfQzdLUENmVHcxZ0dRNGZ0Unl5UTFweFlfcHkyNDZRRTNpQVFjbXVickRvbnktdFNKWXVVVWVhQldQV1ZCZmR0M24zaGtyTWVlMVA2RllLY2JlNlBscmpKdHZGUkNQdjdYU3d0NGJ6RTZ6aFNMaVFaeE5IdWV3clhfcXBQTVgwTm1fYnZBX1dzMDd2ZkpYLTJJQ1RiSDRiU0hrZ2tCSlBPRS1LOGRRams0RGNYTmtXSGc?oc=5" target="_blank">Dyne Therapeutics Announces Completion of Enrollment in</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Phase 3 trial of experimental DM1 treatment fails to hit main goal
Muscular Dystrophy Newstech

Phase 3 trial of experimental DM1 treatment fails to hit main goal

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPZklKcmtMSEZIeERtSlVLUVBBcjFWMlRZUjFmUTlwU05xTTFnNV9pZXhsM2MwRlBZOFJPd3BwYk5RWlkxTFFzdlhGY2g5WHZ0M3lVUy10ejdfcERJVnJ6VlJGbTFRMEx3TEVXTm1JSWhHSzk0V2JOX0pNbmgzMkdNMW11a215OWV4UURYZzQ5S1FzM1dBRm1Vdlc5NWNmQ0haR1E?oc=5" target="_blank">Phase 3 trial of experimental DM1 treatment fails to hit main goal</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting
NeurologyLivegeneral

Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQVllLN2JCT1o3X3l3UnNLdHZJVWlJSmtzdjJkZWVJUHBPOXJDdVlZR1FPenlSWDZicWtSaHhTdmUtSTZqMk1sREpGazk1TE5URE0yV0Q3bGVfbThpSERRSTREUUxleVBCZEJObjZRWVIyTVNlTVFrVUZKb3FIaFhhS19BRjFnMEhkX2NkVTg0MFY2QmlFVGhieg?oc=5" target="_blank">Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape
NeurologyLivegeneral

8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPU0w4NmdWWFNPVXFwSGRLRzFDZzBiSDU1emRiTUJsU0JUay1qN0llbFhfQVQtMF9RQllFTkxJdS1BSzg0WlRBZ2FpU3E2OHBGYVlhTVllV3UxdDVoaXpBS2E5NDc5ZzZUZEx3czV1bDZsYllIWnh5b3Qtc3lWU2JTb3VUS0U2eEQzRWRwN2RBYWVKSDR6dnljZEpGWFhuTE5pNEM1OA?oc=5" target="_blank">8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Del-desiran for myotonic dystrophy type 1
Muscular Dystrophy Newsgeneral

Del-desiran for myotonic dystrophy type 1

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOenFKdEhHSHFZQ01MNGdnZ2VxdjdfcTRJSU52NHBYWnFId2s5N1pfeHZLV0VfeFR4MU05d0JNN21tbzZYQzVGeElvS1k5QndHbHNyZTVNM0RaM2FPOFItR29pQ3VvY2ZXTndLV2RqektJWFBFM0NMWkRZemFyV2hpQWR3?oc=5" target="_blank">Del-desiran for myotonic dystrophy type 1</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
AMO Pharma Aligns With Regulators on Registrational Study for AMO-02 in Myotonic Dystrophy
NeurologyLivegeneral

AMO Pharma Aligns With Regulators on Registrational Study for AMO-02 in Myotonic Dystrophy

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPazFvRnVDZ1dUdmdtZGFVdEdjMXZTb3NpdFc0QW5hR2lWQk1iXzhLcEFna1JYenhJOFloUmJYd19vWDFtWWg0ZllaM01XeXdUcG94c0dEakk3R3dTc1Q0RDRmTGx6cTl5TEo0YjZYa0FFcTg5QmVwc1pzaGlBOS1RcDM1Z2ZkdDFzZjRvczdWUnBaMmpwWUVZSy05ZTZqUjZXd0VqUWtCckdkQ0F1UE1OYzlGQlpvZw?oc=5" target="_blank">AMO Pharma Aligns With Regulators on Registrational Study for AMO-02 in Myotonic Dystrophy</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Avidity to Begin Phase 3 HARBOR Trial in Myotonic Dystrophy Following Positive MARINA Results
NeurologyLivegeneral

Avidity to Begin Phase 3 HARBOR Trial in Myotonic Dystrophy Following Positive MARINA Results

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOU0xoS3dYem8zREx5VzU4bjNaeGVQTEROSFJrUTRJSHRsbDZXazUybHZIaTU1amlOeEtyTk05Y0V4dGFLc3pWbVp6XzMxVHM2a21WeEVjRmotV1VTY1B5ZVFHRVhaX1FvbEtyVzVaQ2Q3Q1FWRW1WR0xRNGpCLTZEMnVTX3AtamFuS2ZWTGs1WnUxVFNVSmpDa2drSHdvRTcxSlpMY1B5SWN6X0c4aTBQT3F3?oc=5" target="_blank">Avidity to Begin Phase 3 HARBOR Trial in Myotonic Dystrophy Following Positive MARINA Results</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
PR Newswirescience

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

<a href="https://news.google.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?oc=5" target="_blank">Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
AMO-02 for myotonic dystrophy type 1
Muscular Dystrophy Newsgeneral

AMO-02 for myotonic dystrophy type 1

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE5ZdTM5UnhuWGo4dndNRERjSmotUmtJTlNidVFQMVJGZG5nUnhwcGxDU05CRWxmNU9NVlp2aFowLV8xa2F6ZnVYZm8wQTFmQ1BNLUNZTTBaUHVZVDV2bnhDdTV0X1pxOEI3SEdNZnhVNGpwbmVCZ0JaaWFGRQ?oc=5" target="_blank">AMO-02 for myotonic dystrophy type 1</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
Assessing Phase 2/3 Trial Safety and Efficacy of AMO-02 for Myotonic Dystrophy: Mike Snape, PhD
NeurologyLivegeneral

Assessing Phase 2/3 Trial Safety and Efficacy of AMO-02 for Myotonic Dystrophy: Mike Snape, PhD

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNWUc1cGRVZ3RIZENNLW41LVRGbmpCekRzMzlvOC1LcDhNN2RfRExjdnlWRFFkd01QQWxXeEJ3TEsydFVJdmMwd1RsSHdnMm9tbDJ5dG1mY28xbEs1Y1E3WmQ3TDczOUZESG5GTW9rSDFoRU9UVWtFS0t3Sjl0dy1JanlQcThxVndCRXNDZ3c4REE1YkZZVVNQTTI2b2xVSHV3RC1SXzhReWFUSlRERkFua3p4OA?oc=5" target="_blank">Assessing Phase 2/3 Trial Safety and Efficacy of AMO-02 for Myotonic Dystrophy: Mike Snape, PhD</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Dyne Therapeutics to Present Additional One-Year Clinical
GlobeNewswiregeneral

Dyne Therapeutics to Present Additional One-Year Clinical

<a href="https://news.google.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?oc=5" target="_blank">Dyne Therapeutics to Present Additional One-Year Clinical</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Potential Path for Phase 3 Study of AOC 1001 in Myotonic Dystrophy Becomes Clear After FDA Ease’s Clinical Hold
NeurologyLivegeneral

Potential Path for Phase 3 Study of AOC 1001 in Myotonic Dystrophy Becomes Clear After FDA Ease’s Clinical Hold

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPblJRVVNqLXN4b0QzSGNlNHNESmZaM2Fxa0Iwa3FTdXRqb1hHNmRwNEZwQ0pjSkxXQnd5YlU5ektJOXZOZVZNVmNSaGRWRjRoVFlCSmZFdXoyaXhRakhBTWlzdFFjNEYyVG1FTHA2d3RPR2dya2RGZzUybnRRUnJZU0tXT01hMkhNcmNaRzJJel9aeFZqdDJCWVFITnpIT3BzOWpyb05OaHIzMkVZcXFQR3JpVjItZDBLOG9rUk1BZWt5OVlENjVBSTRjYjBrdw?oc=5" target="_blank">Potential Path for Phase 3 Study of AOC 1001 in Myotonic Dystrophy Becomes Clear After FDA Ease’s Clinical Hold</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
AMO Pharma to start AMO-02 Phase 3 trial in adult-onset DM1
Muscular Dystrophy Newsgeneral

AMO Pharma to start AMO-02 Phase 3 trial in adult-onset DM1

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNeVlZTXppQkgteEl3anQyWUVLY3IzQk5ta0V3Y1FyVjVydTI3WnFyODJ1ZXNUMzlmcXg1ekZyZlUxNTAwQ0k4ZW1LX0RSdWRkX2R4NllQTVhPcGVLbHZ5d3g1ODV5N25GV0pBSXBUb0JNYnVfWEk2ajZFdUdDcWJlYjRqb3ZDRXBkQU1XaUc2bjZmYzFHbDRaQw?oc=5" target="_blank">AMO Pharma to start AMO-02 Phase 3 trial in adult-onset DM1</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
Avidity’s del-desiran for DM1 named orphan drug in Japan
Muscular Dystrophy Newsgeneral

Avidity’s del-desiran for DM1 named orphan drug in Japan

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNVXVSbUZaVl9oSGtPUk1wZUpBNmxzWEFta1EwTl9FVnJpZlB1RVAtalZrd0lSd3dGZUZlY2FQOU1YNjluNlVPNjIycDVVbUhmRXVvcFhRQ3c4NXVuVUQwZXlJUGhNRmQ1NGVmNVBwQ0h3Y2JYd1J6aTR6czNwclR4UlZfOF9pT3JoZTVQVXVCbUlyMHQ2QVNyWTluUmk?oc=5" target="_blank">Avidity’s del-desiran for DM1 named orphan drug in Japan</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight
PR Newswiregeneral

Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight

<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxQaHAweXUwLXpfTXF1RFdVaUJ1M196ajJ6OEV4eVRyNXJmdXJMbldMU3dod3k2b0h1TUJ6VW9YUERxQXBEMno0WW9faVc0Tl9UaWMwU1hNZ2NSRVNwVk82NVpGckRGV2tXRGdGcVlRUFQ1dlFxYnJqaDM5X19xXzVhTWJ0aTY3WUhlZ1ptVmJYTThIYUh1VTJEcEQ1NE5oUlhmN1dBdjRfMTVQUm5OdUFka0JIZ243X2V1M0FwenVrWU1XQ3dlR3IzMGF3V0JDQi1LbGZ4eFFkUnhBSnd0QTJUcENrelhkczR3bzlqWmJTX3VpM3lCaFlUaEVVMnhERWdRbTFScFlSbHdYWnRsX3FYbEdUTQ?oc=5" target="_blank">Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Del-desiran for DM1 wins FDA’s breakthrough therapy designation
Muscular Dystrophy Newsgeneral

Del-desiran for DM1 wins FDA’s breakthrough therapy designation

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPeURfYVBkM2UtZWZMQ2JmUHJJZWlCSlRrQVpyZlFtclZPQWoxRmo1VUM2MWNtd1l4Q1FnZkNnM3lmZzlQVkppUXhidHctSTRBc0V1VHJIcjlmOHE0cWszRkJRNWpLVExRMG1vcnV6dkhzY3pUMzhQcnRNLVlTX0J4b1ZVOWtYaTJVLXJzcWVEN1VpU2ZUaEhFYVkwYjRmMktabW5B?oc=5" target="_blank">Del-desiran for DM1 wins FDA’s breakthrough therapy designation</a>  <font color="#6f6f6f">Muscular Dystrophy News</font>

Read Full StoryMore like this
Evaluating the Therapeutic Potential of Del-Desiran in Myotonic Dystrophy Type 1: The HARBOR Trial
NeurologyLivegeneral

Evaluating the Therapeutic Potential of Del-Desiran in Myotonic Dystrophy Type 1: The HARBOR Trial

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQV1ByY3hwUWxYekFna00zd1NkUkd2VUNQb1JfMlhscVpLQVc0dmNyeWlMMWJJWUpPZ1NkSGZzQ2ZNSUUxaElNcWlQVGpxZ2FFZGdwNEFrTlBvbURpR0lGTUxadDNFVUJqN2FRcjB5NWtfWEtPNkxjUHFxa1d4b1J3a28xOTdjNGVPd2dBanJ2SzAwOTEtSVk2STBWNm0?oc=5" target="_blank">Evaluating the Therapeutic Potential of Del-Desiran in Myotonic Dystrophy Type 1: The HARBOR Trial</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
"Phase 3 Trial for Myotoni" — Live Google News Trends & Headlines